ChemDmart
Chemxpert Database
  • About
    • About
    • Leadership
    • Advisory Board
  • Products
    • ChemProtel - Product Intelligence
    • CompFolio - One Company Profile
    • CompGroupe - Group Company Profile
    • ChemScape - Data Landscape
    • ChemDmart - E-Market Place
    • DataIntel - Data Analytics/Trends
    • DataFeed - Data News/Feed
    • CompShow- Company Showcase
  • Sources
  • Subscription
  • User Guide
  • Contact
  • Book Demo Log In
  1. Home
  2. All News
  3. Bayer Scores Eu Approval For Ckd Drug Kerendia
News Feed
course image
  • 23 Feb 2022
  • Admin
  • News Article

Bayer scores EU approval for CKD drug Kerendia

EU regulators have approved Bayer's Kerendia (finerenone) to treat adults with chronic kidney disease associated with type 2 diabetes, the company announced Monday. The decision comes on the heels of a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use, and follows FDA approval of the oral drug for the same indication last year. Michael Devoy, head of medical affairs and pharmacovigilance at Bayer's pharmaceuticals division, said the EU approval of Kerendia "offers physicians a new path to protect these vulnerable patients by reducing their risk of cardiovascular (CV) events and delaying kidney disease progression." Kerendia works by blocking the mineralocorticoid receptor overactivation thought to contribute to CKD progression and CV damage. Bayer's filing was supported by data from the Phase III FIDELIO-DKD trial, comparing Kerendia to placebo when added to standard care in around 5700 CKD patients with type 2 diabetes. Results showed that significantly fewer patients in the Kerendia group progressed to a composite endpoint that included a minimum 40% reduction in kidney function, onset of kidney failure, or kidney death. The drug has also succeeded in the Phase III FIGARO-DKD study of CKD patients with type 2 diabetes. Detailed findings unveiled last year showed that Kerendia significantly reduced the risk of the composite primary endpoint of time to first occurrence of CV death or nonfatal CV events by 13% over a median follow-up of 3.4 years when added to ACE inhibitors or angiotensin receptor blockers. Bayer noted that its treatment has also been submitted for marketing authorisation in China and other countries

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!

Categories

image
Product Related Updates
image
Certificates/Accreditation
image
Approval/Launch
image
Clinical Trial Update
image
Licensing/Partnering/Collaboration Deal
image
ODD/BTA/FTA Status
image
Merger/Acquisition
image
Warning/Recalls

Lifescience Intellipedia Pvt. Ltd.

C-89, Sector-65 Noida-U.P. 201301 (India)
Toll-Free: 18004190155
Phone: +91-120-6631301-361
Mobile: +91-9990237670
Email: info@lifescienceintellipedia.com
Email: sales@lifescienceintellipedia.com

USEFUL LINKS

  • Home
  • Privacy Policy
  • Terms & Conditions
  • Terms Of Use
  • Refund Policy
  • Blogs

OUR PRODUCTS

  • ChemProtel - Product Intelligence
  • CompFolio - One Company Profile
  • CompGroupe - Group Company Profile
  • ChemScape - Data Landscape
  • ChemDmart - E-Market Place
  • DataIntel - Data Analytics/Trends
  • DataFeed - Data News/Feed
  • CompShow- Company Showcase

LOCATION

© Copyright Lifescience Intellipedia Pvt. Ltd.. All Rights Reserved

Fill The Form